Genmab A/S Sponsored ADR (NASDAQ:GMAB) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) have received an average rating of “Moderate Buy” from the eleven research firms that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $39.75.

A number of research firms recently weighed in on GMAB. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Genmab A/S in a research report on Wednesday, October 8th. Truist Financial restated a “buy” rating and issued a $48.00 price objective (down previously from $49.00) on shares of Genmab A/S in a report on Thursday, November 6th. Guggenheim raised Genmab A/S from a “neutral” rating to a “buy” rating and set a $43.00 price target for the company in a research report on Tuesday, September 23rd. HC Wainwright raised their price target on Genmab A/S from $40.00 to $41.00 and gave the company a “buy” rating in a research note on Monday, November 10th. Finally, Wall Street Zen upgraded Genmab A/S from a “hold” rating to a “buy” rating in a research note on Saturday, November 22nd.

Genmab A/S Trading Up 1.1%

NASDAQ:GMAB opened at $32.02 on Friday. Genmab A/S has a 1-year low of $17.24 and a 1-year high of $33.65. The firm has a market capitalization of $20.57 billion, a price-to-earnings ratio of 13.63, a PEG ratio of 1.65 and a beta of 0.90. The business’s 50-day moving average price is $30.78 and its two-hundred day moving average price is $25.83.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Thursday, November 6th. The company reported $0.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.17. The company had revenue of $1.02 billion during the quarter, compared to analyst estimates of $975.40 million. Genmab A/S had a net margin of 41.36% and a return on equity of 23.98%. Sell-side analysts predict that Genmab A/S will post 1.45 earnings per share for the current year.

Hedge Funds Weigh In On Genmab A/S

A number of large investors have recently made changes to their positions in GMAB. Headlands Technologies LLC boosted its holdings in Genmab A/S by 1,525.0% in the 1st quarter. Headlands Technologies LLC now owns 1,560 shares of the company’s stock valued at $31,000 after purchasing an additional 1,464 shares during the period. Osaic Holdings Inc. grew its position in Genmab A/S by 37.8% in the second quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock valued at $33,000 after acquiring an additional 440 shares during the last quarter. CWM LLC lifted its stake in Genmab A/S by 50.5% in the 2nd quarter. CWM LLC now owns 1,797 shares of the company’s stock valued at $37,000 after purchasing an additional 603 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its position in Genmab A/S by 124.3% in the first quarter. Caitong International Asset Management Co. Ltd now owns 1,931 shares of the company’s stock valued at $38,000 after buying an additional 1,070 shares in the last quarter. Finally, NewEdge Advisors LLC grew its stake in shares of Genmab A/S by 1,229.0% during the third quarter. NewEdge Advisors LLC now owns 1,236 shares of the company’s stock worth $38,000 after buying an additional 1,143 shares during the last quarter. Institutional investors own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.